IRONWOOD PHARMACEUTICALS INC
IRONWOOD PHARMACEUTICALS INC (IRWD): 4 pipeline candidates · 1 upcoming catalyst · ~22 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.4 months
1% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~2616d
0 buys · 15 sells (180d)
A transparent, data-derived signal for IRONWOOD PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$608.2M
Cash
$220.5M
Quarterly Burn
$34.0M
Runway
22.4 mo
Revenue
$106.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| apraglutide | Phase 3 |
| CNP-104 | Phase 2 |
| IW-3300 | Phase 2 |
| LINZESS | Approved |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
224
Total value held
$599.1M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 15,028,000 | $52.7M |
| blackrock, inc. | 13,362,930 | $46.9M |
| vanguard capital management llc | 12,194,908 | $42.8M |
| ubs group ag | 12,133,545 | $42.6M |
| sarissa capital management lp | 9,188,635 | $32.3M |
| bank of america corp /de/ | 8,682,907 | $30.5M |
| renaissance technologies llc | 8,061,073 | $28.3M |
| aqr capital management llc | 7,535,080 | $26.4M |
| state street corp | 7,456,944 | $26.2M |
| vanguard portfolio management llc | 6,682,037 | $23.5M |
Showing top 10 of 224 institutional holders of IRONWOOD PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in IRONWOOD PHARMACEUTICALS INC's pipeline?
IRONWOOD PHARMACEUTICALS INC (IRWD) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IRONWOOD PHARMACEUTICALS INC's lead drug candidate?
IRONWOOD PHARMACEUTICALS INC's most advanced tracked candidate is apraglutide (Phase 3) for short bowel syndrome with intestinal failure (SBS-IF).
What is IRONWOOD PHARMACEUTICALS INC's next catalyst?
IRONWOOD PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: LINZESS" — expected August 16, 2033.
What is IRONWOOD PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IRONWOOD PHARMACEUTICALS INC has approximately 22.4 months of cash runway.
What is IRONWOOD PHARMACEUTICALS INC's market capitalization?
IRONWOOD PHARMACEUTICALS INC's market capitalization is approximately $608.2M.
Get the full picture on IRONWOOD PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.